Ionis Pharmaceuticals (1IONS) Stock Overview
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
1IONS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Ionis Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$64.26 |
| 52 Week High | US$76.60 |
| 52 Week Low | US$36.41 |
| Beta | 0.40 |
| 1 Month Change | 1.61% |
| 3 Month Change | -4.38% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 148.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1IONS | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | -0.6% | 3.7% | 1.9% |
| 1Y | n/a | 39.2% | 29.6% |
Return vs Industry: Insufficient data to determine how 1IONS performed against the Italian Biotechs industry.
Return vs Market: Insufficient data to determine how 1IONS performed against the Italian Market.
Price Volatility
| 1IONS volatility | |
|---|---|
| 1IONS Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in IT Market | 7.9% |
| 10% least volatile stocks in IT Market | 3.0% |
Stable Share Price: 1IONS has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: 1IONS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 1,402 | Brett Monia | www.ionis.com |
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy.
Ionis Pharmaceuticals, Inc. Fundamentals Summary
| 1IONS fundamental statistics | |
|---|---|
| Market cap | €10.74b |
| Earnings (TTM) | -€323.15m |
| Revenue (TTM) | €799.61m |
Is 1IONS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1IONS income statement (TTM) | |
|---|---|
| Revenue | US$943.71m |
| Cost of Revenue | US$931.53m |
| Gross Profit | US$12.18m |
| Other Expenses | US$393.57m |
| Earnings | -US$381.39m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 29, 2026
| Earnings per share (EPS) | -2.31 |
| Gross Margin | 1.29% |
| Net Profit Margin | -40.41% |
| Debt/Equity Ratio | 479.3% |
How did 1IONS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/15 21:45 |
| End of Day Share Price | 2026/04/15 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ionis Pharmaceuticals, Inc. is covered by 42 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | Barclays |
| Eliana Merle | Barclays |
| Huidong Wang | Barclays |